Clinical Trial Update: DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer

View source ↗

Summary

This clinical trial update evaluates DNA promoter hypermethylation as a blood-based biomarker for pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: Aalborg University Hospital | Conditions: Pancreatic Diseases, Pancreatic Neoplasms | Status: UNKNOWN